Oxford Biomedica (LON:OXB) Shares Break Below Two Hundred Day Moving Average - Here's What Happened

Key Points

• Oxford Biomedica shares fell below their 200-day moving average of GBX 564.56, reaching GBX 502 before closing at GBX 511 on trading volume of 349,560 shares.
• Analysts maintain a generally positive outlook, with three Buy ratings and one Hold rating producing a “Moderate Buy” consensus and an average price target of GBX 613.32.
• The company reported a quarterly loss of GBX 30.39 per share, alongside a negative net margin and return on equity. Insider Roch Doliveux bought 20,250 shares at GBX 505, while insiders collectively own 25.83% of the company.

Shares of Oxford Biomedica plc (LON:OXB - Get Free Report) crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of GBX 564.56 and traded as low as GBX 502. Oxford Biomedica shares last traded at GBX 511, with a volume of 349,560 shares traded.

Wall Street Analyst Weigh In

Several research analysts have weighed in on OXB shares. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a GBX 595 price target on shares of Oxford Biomedica in a report on Wednesday, September 2nd. Royal Bank Of Canada reissued an "outperform" rating and issued a GBX 900 price target on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of GBX 613.32.

Oxford Biomedica Stock Performance

The stock's 50-day moving average is GBX 492.26 and its 200-day moving average is GBX 564.56. The stock has a market cap of £618.56 million, a price-to-earnings ratio of -15.99 and a beta of 1.11. The company has a current ratio of 2.21, a quick ratio of 1.67 and a debt-to-equity ratio of 273.08.

Oxford Biomedica (LON:OXB - Get Free Report) last posted its quarterly earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) EPS for the quarter. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%. On average, analysts expect that Oxford Biomedica plc will post -31.08 EPS for the current year.

Insider Transactions at Oxford Biomedica

In related news, insider Roch Doliveux purchased 20,250 shares of the stock in a transaction that occurred on Wednesday, September 23rd. The stock was purchased at an average cost of GBX 505 per share, for a total transaction of £102,262.50. Corporate insiders own 25.83% of the company's stock.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.